Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

ConditionInteraction
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-64
SponsorWashington State University

About this trial

The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.

Eligibility criteria

Qualifiers

Between 18-64 years old and healthy

Not taking any medications (prescription and non-prescription) or dietary/herbal supplements that can interfere with study drug pharmacokinetics

Willing to abstain from consuming dietary/herbal supplements and citrus juices for several weeks

Willing to abstain from cannabis/marijuana, hemp, and THC- and CBD-containing products for several weeks

Disqualifiers

Under 18 or over 64 years old

Taking medications or dietary/herbal supplements that can interfere with study drug pharmacokinetics

Have a major illness

Taking medication/supplements for a mineral deficiency

Trial design

Treatments tested in this trial

  • Oregano
  • Drug cocktail

Treatment groups

16 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Washington State University

Lead sponsor

Office of Dietary Supplements (ODS)

Collaborator

National Center for Complementary and Integrative Health (NCCIH)

Collaborator